Myomo, Inc., a commercial stage medical robotics company, designs, develops, and produces myoelectric braces or orthotics for people suffering with neuromuscular disorders in the United States. It offers MyoPro, a powered upper limb orthosis that supports the arm, as well as restores function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain injury, spinal cord injury, ALS, or other neuromuscular disease or injury. The company serves orthotics and prosthetics practices or clinics, as well as the veteran administration and other hospitals through orthotics and prosthetics providers, and distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NYSEAMERICAN
Industry Medical Devices
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:MYO
CUSIPN/A
Phone+1-617-9969058
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-257.70%
Return on Equity-155.42%
Return on Assets-73.21%
Miscellaneous
EmployeesN/A
Outstanding Shares12,410,000
Market Cap$24.74 million
Myomo (NYSEAMERICAN:MYO) Frequently Asked Questions
What is Myomo's stock symbol?
Myomo trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MYO."
How were Myomo's earnings last quarter?
Myomo Inc (NYSEAMERICAN:MYO) posted its earnings results on Tuesday, August, 7th. The company reported ($0.21) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.19) by $0.02. The company earned $0.63 million during the quarter, compared to analysts' expectations of $0.62 million. Myomo had a negative return on equity of 155.42% and a negative net margin of 257.70%. View Myomo's Earnings History.
When is Myomo's next earnings date?
What price target have analysts set for MYO?
2 Wall Street analysts have issued 1 year price objectives for Myomo's stock. Their forecasts range from $7.00 to $12.00. On average, they expect Myomo's stock price to reach $9.50 in the next twelve months. This suggests a possible upside of 392.2% from the stock's current price. View Analyst Price Targets for Myomo.
What is the consensus analysts' recommendation for Myomo?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myomo in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Myomo.
Are investors shorting Myomo?
Myomo saw a increase in short interest during the month of July. As of July 31st, there was short interest totalling 1,030,968 shares, an increase of 21.9% from the July 13th total of 845,694 shares. Based on an average daily volume of 257,188 shares, the short-interest ratio is presently 4.0 days. Approximately 10.0% of the shares of the company are short sold. View Myomo's Current Options Chain.
Who are some of Myomo's key competitors?
Some companies that are related to Myomo include Creo Medical Group (CREO), Hamilton Thorne (HTL), Kromek Group (KMK), Electromed (ELMD), Universal Biosensors (UBI), Advanced Oncotherapy (AVO), Protech Home Medical (PHM), MRI Interventions (MRIC), Surgical Innovations Group (SUN), Neuroone Medical Technologies (NMTC), PetVivo (PETV), Avacta Group (AVCT), GI Dynamics (GID), Airware Labs (AIRW) and Inspiration Healthcare Group (IHC).
Who are Myomo's key executives?
Myomo's management team includes the folowing people:
- Mr. Paul R. Gudonis, Chairman, Pres & CEO (Age 63)
- Ms. Davie Mendelsohn RN, VP of Sales & Clinical Services (Age 64)
- Mr. Jonathan Naft, VP & GM (Age 53)
- Mr. Ralph A. Goldwasser, Chief Financial Officer (Age 70)
- Mr. Clifford J. Conneighton, Chief Marketing Officer (Age 68)
Has Myomo been receiving favorable news coverage?
Headlines about MYO stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Myomo earned a media and rumor sentiment score of 0.06 on Accern's scale. They also gave media coverage about the company an impact score of 47.51 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. View Recent Headlines for Myomo.
Who are Myomo's major shareholders?
Myomo's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Account Management LLC (0.85%).
Which institutional investors are buying Myomo stock?
MYO stock was acquired by a variety of institutional investors in the last quarter, including Account Management LLC.
How do I buy shares of Myomo?
Shares of MYO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Myomo's stock price today?
One share of MYO stock can currently be purchased for approximately $1.93.
How big of a company is Myomo?
Myomo has a market capitalization of $24.74 million.
How can I contact Myomo?
Myomo's mailing address is One Broadway, 14Th Floor, CAMBRIDGE, MA 02142, United States. The company can be reached via phone at +1-617-9969058.
MarketBeat Community Rating for Myomo (NYSEAMERICAN MYO)
MarketBeat's community ratings are surveys of what our community members think about Myomo and other stocks. Vote "Outperform" if you believe MYO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYO will underperform the S&P 500 over the long term. You may vote once every thirty days.
